EvaluationofextracorporealmembraneoxygenationapplicationinmarginalhearttransplantationMENGXu,GURBANOVEmin,CUIYong-qiang,HANJie,ZENGWen,JIAYi-xin【Abstract】ObjectiveToreviewtheefficacyandclinicaloutcomesofextracorporealmembraneoxy-genation(ECMO)usedfordonorheartswithlongcoldischemictimes(LCIT)duringhearttransplantation.MethodsFromFebruary2005toApril2009,11patientswerereceivedallograftswithLCITover7hoursun-derwentbothintraoperativeECMOcircuittreatmentandECMOsupportpostoperation(i-ECMOgroup).Another11patientswithischemiatimeofheartgraftslessthansevenhourswerereceivedpostoperationECMOsupportasasalvagetherapyafterperioperativestandardcardiopulmonarybypassCPB(s-CPBgroup).RateofweaningECMO,lengthofICUstay,volumeofpackedredbloodcell(PRBC)transfusion,leftventricularejec-tionfraction(LVEF),costofhospitalization,rateofperioperativesurvivalandrateof1-yearpostoperativesur-vivalwerecomparedbetweenthetwogroups.ECMO-relatedcomplicationswereobserved.ResultsTherewasasignificantdifferenceincoldischemictimebetweenthetwogroups(P<0.01),withcoldischemictimeran-gingfrom422to485minutes(mean448minutes)ini-ECMOgroupwhile110to400minutes(mean218mi-nutes)ins-CPBgroup.Tenpatients(91%)ini-ECMOgroupwereweanedoffECMOandallsurvivedtodis-charge.Onlyapatientinthisgroupdiedofmassiveintraoperativebleeding(notECMO-related).Rateofwea-ningECMOinthes-CPBgroupwas82%(9/11).TheoverallweaningrateofECMOapplicationduringhearttransplantationwas86%.Theoverall30-dayand1-yearsurvivalratesfori-ECMOands-CPBgroupswere91%and82%,73%and64%,respectively.Therewasnodifferenceinmortalitybetweenthetwogroups(P>0.05).Comparedwiths-CPBgroup,thelengthofstayinICU,therequirementforPRBCadministrationandthetotalin-hospitalcostweresignificantlyreducedinthei-ECMOgroup(P<0.05).ThepreoperativeandpostoperativeLVEFofi-ECMOands-CPBgroupswere0.23±0.06and0.25±0.10,0.65±0.12and0.66±0.06,respectively.LVEFofbothgroupssignificantlyimprovedafteroperation.Anintra-aorticballoonpump(IABP)wasappliedduetolowcardiacoutputin5patients(23%),amongthem3patientsweanedfromEC-MOexceptanothertwopatients.Among6patients(27%)whorequiredcontinuousrenalrepacementtherapy(CRRT)duetorenaldysfunction,2wereweanedfromECMOand4couldnotbeweaned.ConclusionsAp-plicationofECMOinpostoperativeperiodprovidesearly,continuedandeffectivesupportfordonorheartswithLCITandefficientlymakesuseofsuchmarginalorgans.ReducedlengthofICUstay,reducedtransfusionvol-umeofPRBCandreducedin-hospitalcostareadditionaladvantagesofthistechnique.【Keywords】Hearttransplantation;Marginaldonor;Extracorporealmembraneoxygenation;CardiopulmonarybypassDOI:10.3969/j.issn.1674-7445.2010.03.007Authoraffiliations:DepartmentofCardiovascularSurgery,BeijingAnzhen,CapitalUniversityofMedicalScience,Beijing100029,ChinaCorrespondingauthor:MENGXu,E-mail:mxu@263.netThecriticalshortageofdonorgraftsurgestrans-plantationsurgeonstousesuboptimalorso-calledmar-ginalheartswithcoldischemictime(CIT)overcon-ventionallimits[1].Donorheartswithlongcoldische-mictimes(LCIT)areassociatedwithhigherratesofperioperativeacutegraftfailure(PAGF)———amajorcauseofmortalitywithinthefirst30daysaftertrans-plantation[2-4].Useofmechanicalcirculatorysupport(MCS)istheultimatechoiceforPAGFifanyothermedicaltreat-mentfailed.Inthepresentstudy,wereportourcumul-ativeexperiencewiththeuseofextracorporealmem-·158·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3braneoxygenation(ECMO)intheadulthearttrans-plantation(HTx).Furthermore,inordertoimproveoutcomesofdonorheartswithLCIT,weevaluatetheefficacyofastrategybasedonbothintraoperativeextra-corporealmembraneoxygenation(i-ECMO)circuitandpostoperativeECMOcardiopulmonarysupport.MethodsPatientsFromFebruary2005toApril2009atotalof122HTxwereperformedinourdepartment,amongwhichECMOwasutilizedin22patients(18%).Transplantrecipientsincluded17malesand5females,withageof(48±9)years(rangefrom29to70years).AllpatientswerediagnosedasclassⅢ/ⅣaccordingtoNewYorkHeartAssociation(NYHA)assessmentcri-teriapreoperatively.Informedconsenthasbeenob-tainedforallthepatientsbeforeoperation.Thisstudywasapprovedbyaresearchethicscommitteeorinstitu-tionalreviewboard.Datawereretrospectivelycollectedfromthede-partment'sECMOforms.IndicationsforHTxincludeddilatedcardiomyopathy(DCM)in18patients(82%),valvularcardiomyopathy(VCM)in2pa-tients(9%)andischemiccardiomyopathy(ICM)in2patients(9%).Bicavalorthotopichearttransplanta-tionswereperformedinallthepatients.Atripleimmu-nosuppressionregimenwasusedafterHTxincludingciclosporin(CsA),mycophenolatemofetil(MMF)andprednisone.Allpatientsreceivedinterleukin-2(IL-2)receptorblocker(basiliximab)asimmunosup-pressiveinduction.StudygroupsElevenpatientsreceivingdonorheartswithCITover7hoursunderwenti-ECMOsupport(i-ECMOgroup).i-ECMOcircuitforthisgroupspecificallywassetupforconvenientconversiontopostoperativeECMOsupport(describedbelow).Standardcardiopulmonarybypassgroup(s-CPBgroup)consistedof11contem-poraryHTxpatientswhoeitherwerenotabletoweanoffCPBorunderwentfemoralveno-arterialECMO(CB1Q91R6,MedtronicInc.USA)implantationinICUasasalvagetherapy.Theindicationsforpostoper-ativeECMOinthesepatientsareasfollows:systolicbloodpressurelessthan80mmHg(10mmHg=1.33kPa),poormyocardialcontractilitydiagnosedbytran-sthoracicechocardiography(ECHO),centralvenouspressureover267mmH2O,urinaryoutputlessthan0.5ml·kg-1·h-1andfailuretoweanoffCPB.Set-upofi-ECMOcircuitandsubsequentconver-sionintopostoperativeECMOThecircuitwasbasedonacentrifugalbloodpump(CB4649,MedtronicInc.USA),heparin-coatedtubes(CB2994,MedtronicInc.USA)andcardiotomyreservoirwithintegratedmembraneoxygenatorandheatexchanger(541T,Medtronic,Inc.USA).Thearterialreturncannulawasinserteddirectlyintotheascendingaortaanduseduntiltheremovaloftheaorticcross-clampduringthecardiacarrest.Venousdrainagefromtheinferiorvenacava(IVC)wasachievedwitha19For21Fcannula(CB96560,MedtronicInc.USA)insert-eddirectlyintothefemoralveinwithplacementofthetipjustproximaltotherightatrium.Thesecondve-nousdrainagewasperformedwithcannulainsertedintothesuperiorvenacava(SVC).Thefemoralarterywasalsosurgicallyexposedandpreservedduringacutdownoffemoralveinforthelatercannulation.Excepttheor-dinarynon-heparincoatedSVCcannula,boththeaor-ticarteryandIVCcannulaswereheparin-coated.Acardiotomyreservoirwasinsertedinthevenouslineandthehemofilterwasplacedinthearterialline.Es-tablishingsuchacircuitpatientsini-ECMOgroupwereallowedimplementationofcardiotomysuctionandim-mediatereturnofthelostfullyheparinizedchestcavitybloodintothereservoir.AttheendofoperationtheconventionalECMOsupportwascreatedusingthefollowingprocedures:thearterialcannulawastransferredintofemoralarterialcannulationviathepriorcutdownoffemoralarteryandthecardiotomyreservoirwithitslinesandhemofilterwasremoved.Femoralveincannulationremainedin-tactandwasconnectedtothevenousline.ChestwasclosedandpatientsweretransferredtoICUwardswithfemoralveno-arterialECMOsupport(Figure1).·159·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3Figure1AschematicillustrationofthestandardCPBcircuit,i-ECMOcircuitanditssubsequentconversionintopostoperativeECMOLegends:Ⅰ:standardCPB;Ⅱ:i-ECMO;Ⅲ:conversionfromi-ECMOintopostoperativeECMO(discardedhemofilterandcardiotomyreservoir);AO:aorta;SVC:superiorvenacava;IVC:inferiorvenacava;FA:femoralartery;FV:femoralvein;TMC:tri-opticmeasurementcellManagementofECMOandweaningVentilatorsettingswerereducedtominimum.Minimalinotropicsupport(dopamine5mg·kg-1·min-1)wascontinuedduringECMOsupporttomain-tainleftventricularejectionagainstincreasedafterloadandtopreventoverdistension.Adistalcannulaforop-timizationoflowerlimbwasusedifearlysignsofische-miawereobserved.Intravenousheparinwasadminis-teredcontinuouslytomaintainanactivatedclottingtimeof180to220seconds.PatientswereweanedfromECMOsupportoncetheywerehemodynamicallystableonminimalECMOflow(5ml·kg-1·min-1)withgoodrecoveryofmyocardialcontractilityasmonitoredbyECHO.ObservationitemRateofweaningECMO,lengthofICUstay,vo-Ilumeofpackedredbloodcell(PRBC)transfusion,leftventricularejectionfraction(LVEF),costofhos-pitalization,rateofperioperativesurvivalandrateof1-yearpostoperativesurvivalwerecomparedbetweenthetwogroups.ECMO-relatedcomplicationswereob-served.StatisticalanalysisStatisticalanalyseswereperformedbySPSS12.0forWindows.Descriptivestatisticswereusedtoana-lyzethepatients'coursesandclinicaloutcomes.Con-tinuousvariableswereexpressedasmean±SDandwereevaluatedbyStudent'stortheWilcoxonranksumtests.Categoricalvariablesareexpressedasper-centagesandwereevaluatedwiththeχ2orFisher'sex-acttest.P<0.05wasconsideredstatisticallysignifi-cantinallanalyses.ResultsGeneralpatient'sdataandtwogroupsoutcomesNodifferenceswereobservedbetweenthetwogroupsindonorgender(male73%vs82%),ageandthecauseofdeath.Meanageofdonorinbothgroupswas(32±3)years.TherewasasignificantdifferenceinCITbetweenthetwogroups(P<0.01),·160·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3withCITrangingfrom422to485minutes(mean448minutes)ini-ECMOgroupwhile110to400minutes(mean218minutes)ins-CPBgroup.Althoughpatientsini-ECMOshowedalowerLVEFandahigherpulmonaryarterialpressure(PAP),nosignificantdifferencewasobserved(Table1).Table1Comparisonsofdemographicdataandpreoperativecharacteristicsbetweentwogroups(x±s)Datai-ECMO(n=11)s-CPB(n=11)PvalueWeight(kg)70±1671±17>0.05LVEF0.23±0.060.25±0.10>0.05PAP(mmHg)55±949±17>0.05NYHAstatus3.6±0.53.3±0.5>0.05Totalbilirubin(μmol/L)26±1027±9>0.05Serumcreatinine(μmol/L)96±2275±45>0.05CIT(min)448±24218±81<0.01Tenoutof11patients(91%)ini-ECMOgroupweanedoffECMOandallsurvivedtodischarge.ThecauseoftheonlydeathinthisgroupwasnotassociatedwithECMOsupport,butwithmassiveintraoperativebleeding(Table2).Ins-CPBgroup,11patientsre-quiredECMOafterthesurgery,including5patients(46%)inwhomECMOwasinitiatedintheconditionthatthepatientswereunabletoweanfromCPB.TheintervalfromcessationofCPBtostartingECMOwasrange0to35hours(mean11hours).WeaningoffECMOwassuccessfulin9patients(82%)and8pa-tients(73%)survivedtohospitaldischarge.Twopa-tientsdiedduringtheECMOsupport,oneduetoliverfailureandtheotherduetocardiacfailure.Thethirdpatientsdiedofoverwhelmingsepsis10daysaftertheweaning.IntraoperativeandpostoperativestatusAlthoughCPBtimes,ventilationtimesandlengthofpostoperativeECMOsupportwereshorterini-ECMOpatients,nosignificantdifferencewasobserved.Post-operativeoutcomesofpatientswereshowninTable3.Overall,weaningratewas86%(19/22)andsurvivaltohospitaldischargewas82%(18/22).The30-dayand1-yearsurvivalfori-ECMOgroupands-CPBgrouppatientswere91%vs73%and82%vs64%respectivelywithnosignificantdifference(allinP>0.05).Overall16patients(73%)wereinNYHAstatusⅠorⅡwithoutanyECMOrelatedcomplicationsat1-yearfollowup,excepttwocasesofdeath.ComplicationsAnintra-aorticballoonpump(IABP)wasap-pliedduetolowcardiacoutputin5patients(23%),Table2i-ECMOgroupdatainHTxpatientsCaseGenderAge(y)CIT(min)DiagnosisLVEFPAP(mmHg)PostHTxstay(d)Outcome1M44480DCM0.156015Wean,survive2F49425VCM0.23501Death(intraoperativebleeding)3M41482DCM0.225526Wean,survive4F38433DCM0.306222Wean,survive5M55441DCM0.206724Wean,survive6M45455DCM0.176229Wean,survive7M49435DCM0.246222Wean,survive8M49424ICM0.333743Wean,survive9M57485DCM0.184327Wean,survive10F70450DCM0.215220Wean,survive11M29422DCM0.275225Wean,surviveLegends:M:male;F:female·161·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3Table3Comparisonsofpostoperativeoutcomesbetweentwogroups(x±s)Datai-ECMO(n=11)s-CPB(n=11)PvalueAorticcross-clampduration(min)94±1492±27>0.05i-ECMO/CPBduration(min)140±26158±42>0.05Ventilationduration(h)25±1247±17>0.05LengthofECMOsupport(h)44±1262±17>0.05LengthofICUstay(h)53±17142±33>0.05TotaltransfusionofPRBC(U)13±632±12<0.05Postoperativehospitalstay(d)23.1±10.127.4±12.1>0.05IntervalfromCPBtoECMO(h)-9.8±3.3<0.05LVEFathospitaldischarge0.65±0.120.66±0.06>0.05Totalin-hospitalcost(USD)26079±554740436±16673<0.05amongthem3patientsweanedfromECMOexceptan-othertwopatients.Among6patients(27%)whore-quiredcontinuousrenalreplacementtherapy(CRRT)duetorenaldysfunction,2(33%)wereweanedfromECMOand4couldnotbeweaned.DiscussionPAGFisthemaincauseofmortalityassociatedwithHTxwithinthefirst30days[5,6].MajorcauseswhichcontributetoPAGFareprimarygraftdysfunction(PGD),rightventricularfailure(RVF)secondarytopulmonaryhypertension(PH)andsevereacuteorhy-peracuterejection.PGDissevereandpoorlyunder-stoodcomplicationgenerallyrelatedtodonorage,poorqualityoftheorgan,weightmismatchandprolongedischemictime.FortreatmentofPAGF,itiscriticaltoimplementearlyMCStoavoidpotentiallyirreversiblegraftinjury.Althoughrightventricularassistdevice(RVAD)seemstohavethemostwidespreaduseinthelitera-ture,theresultsofRVADarestillpoor.Noonandas-sociates[7,8]reportedtheuseofRVADin17and7pa-tientswithcardiacallograftfailurewithamortalityof85%and100%,respectively.Ibrahimetal[9]alsohadthesimilarexperiencereportingallpatientswhoweresupportedbyeitherleftventricularassistdevice(LVAD)orRVADdied.OtherresearchersspeculatedthatPAGFwascom-monlyassociatedwithbiventriculardysfunction,andthuswasgoodcandidateforECMOsupport[10].Tagha-vietal[11]foundECMOtobesuperiortoRVADafterHTx.ResultsoftheirretrospectivestudycomparingRVADwithECMOshowedonly13%RVADpatientsweanedcomparedwith77%ECMOpatientsweaned.AnotherstudybyChouetal[12]alsodemonstratedbet-terresultsintheECMO-treatedgroup.Basedonthesestudiesandduetocapabilitytoprovidebiventricularandpulmonarysupport,ECMOwashighlyrecommend-edasfirst-linechoiceforpatientswithPAGF.Since2005,weextendedECMOusetothepa-tientswithHTxandobservedfavorableclinicalprogno-sis.InthepresentstudyelevenpatientsweretreatedwithECMOaftertransplatation.Eight(73%)patientssurvivedtohospitaldischarge,andthe1-yearsurvivalwas64%.Inanattempttoexpandthedonorpool,donorheartsfrommoreremoteareaswerealsoacceptednow,whichinevitablyextendsischemictimes.MulticenterstudieshadshownthatLCIThadanegativeeffectonearlysurvivalanditwasalsoemphasizedbytheinter-nationalsocietyforheartandlungtransplantation(ISHLT)registry,whichidentifiedischemictimeasanimportantcauseofin-hospitaland1-yearmortalityinHTx[13,14].Theuseofallograftwithischemictimesgreaterthan4to5hourswasreportedtobeassociatedwitharequirementofhigherinotropicsupportwithinthefirst48h,reducedLVEFandrightventricularfunction,prolongedhospitalstay,increasedincidenceofPGDandhighermorbidityandmortality[15-17].Re-cipientsoftendevelopedhypotensionandhemodynamicindiceswereusuallymarginalatthefirstweekafteroperation.Elevenrecipientsreceivedcardiacallograftstrans-plantationwithgraftsischemictimeover7hoursduetolong-distanceprocurement.Importantly,therecipientshadalsomoderatetohighPH.SincesubsequentneedforECMOinthisgroupwasexpected,ani-ECMOcir-cuitwasspecificallysetuponthesepatientsandEC-·162·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3MOsupportwasroutinelyextendedintopostoperativeperiod.Despitei-ECMOgrouppatientshadaconsider-ablenumberofpreoperativeriskfactorsandsignificantLCIT,noincreaseof30-daymortalityinthesepatientswasobservedcomparedtooverallsurvivalreportedinHTx.ThetimingofinitiationofECMObeforecirculato-rycollapseiscriticallyimportanttoavoidorganinjuryanditismostdifficulttodeterminethesuitabletimeforsettingupanECMOsupportforhighriskpatients.Mi-nevetal[18]reported80%mortalityinalltransplantsubgroups,includingthosewithPGD,rightheartfail-ureandacuterejection.Theauthorssuggestedthatatthetimeofinitiationofsupportthesepatientswerege-nerallyinadisastrouscondition,andthattherewasnotimetoadapttothehemodynamicdeterioration.OurexperienceovertheyearsistomakeuseofECMOsup-port,asweopposedtowaitinguntilthepatientdeve-lopsPAGF.ECMOprovidesameansofsupportingthegraftsfunctioninthesepatientsduringacriticalperiodandallowsthefreshlytransplantedhearttoworkunderlessstressfulconditions.ItmayalsobetruethattherecipientsofdonorswithLCITcombinedwithhighpreoperativePHmaynotrequiredECMO.However,patientsini-ECMOgrouphadasignificantlyshorterlengthofstayinICU,re-ducedrequirementforPRBCadministrationandlowertotalin-hospitalcostcomparedwiththepatientswhorequiredECMOasasalvagetherapy.ReducedcostandrapidrecoverywasachievedbyextendingECMOinthepostoperativeperiodinthisgroup,whiles-CPBgrouppatientsrequiredadditionalcostforECMOsup-port.PatientswithPHrequiringintensiveposttransplantmanagementareatsignificanthighriskofacuteRVF[19,20].Salzbergandcolleagues[21]studiedtheroleofLVADsupportasbridgetoHTxinasubsetofpa-tientswithPHandhighpulmonaryvascularresistance(PVR).AperiodofLVADasbridgetoHTxledtonormalizationofpulmonarypressuresandmadethesepatientsamenableforHTx.However,theexpensivebridgingdevicesdoubledthetreatmentexpenses.TheaimofourpresentstudywastoavoidposttransplantRVFbyprovidingimmediatesupportforthetransplan-tedheartandprovidingtimeforadaptationofrightven-tricle(RV).TheeffectofECMOincludesmaximizingcoronaryperfusionthroughmaintenanceofaorticpres-sure,reducingpreloadtoadistendedandischemicRV,decreasingRVafterload,optimizingmyocardialoxygendeliveryandlimitingventricularoxygencon-sumption.Convertinganopenedi-ECMOcircuittoaclosedpostoperativeECMOsupportintheoperatingtheatrehasmanyadvantages.Firstly,itminimizesthepa-tient'sexposuretonewcircuit.Secondly,continuoussupportforgraftswithLCITimproveshemodynamicstabilityfollowingthetransplantation.Thirdly,estab-lishingECMOintheatreratherthaninICUmayreducetheincidenceofinfections.Lastly,thisstrategyismoneysavingandreducestheoverallin-hospitalcost.OtherstudiesalsoreportedtheinitiationofECMOout-sidethetheatrewassignificantlyassociatedwithpooroutcome[22,23].ThemajorlimitationofourstudywasthelackofpropercontrolLCITgroupwithstandardcarewhichwouldultimatelyanswerthequestionofwhetherornoti-ECMOaccountedforimprovedoutcomesinthesemarginaldonors.However,thisstudywasausefulat-tempttoimprovetheoutcomeofmarginaldonorheartsbyutilizingi-ECMOstrategy.Inconclusion,ourresultssuggestedthattheim-plementationofi-ECMOcircuit,whichcanbetrans-formedintoasimple,safe,andeffectivepostoperativeECMOsupport,hadabeneficialeffectoncardiacal-lograftwithLCITcomparedwiths-CPB.Itisrecom-mendabletousei-ECMOinpatientswithhighPHorreceivingmarginaldonorheartsforpromotingthepost-operativefunctionaladaptationofthegraftandavoidingPAGFandRVF.Additionaladvantagesofthistech-niqueincludeshorterexposuretimetoadditionalbloodproductsorsurfaceareaintheprimingofanewextra-corporealcircuit,hemodynamicstabilityandcostre-duction.·163·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3References[1]PetrofskiJA,PatelVS,RussellSD,etal.BVS5000sup-portaftercardiactransplantation[J].JThoracCardiovascSurg,2003,126(2):442-447.[2]TaylorDO,EdwardsLB,BoucekMM,etal.RegistryoftheInternationalSocietyforHeartandLungTransplanta-tion:twenty-secondofficialadulthearttransplantre-port———2005[J].JHeartLungTransplant,2005,24(8):945-955.[3]LuckrazH,GoddardM,CharmanSC,etal.Earlymor-talityaftercardiactransplantation:shouldwedobetter?[J]JHeartLungTransplant,2005,24(4):401-405.[4]LimaB,RajagopalK,PetersenRP,etal.Marginalcar-diacallograftsdonothaveincreasedprimarygraftdys-functioninalternatelisttransplantation[J].Circulation,2006,114(1Suppl):I27-I32.[5]LaksH,MarelliD,FazioD,etal.Expandingtheheartdonorbase[J].CurrOpinOrganTransplant,2000,5(2):134-138.[6]SegoviaJ,PulpónLA,SanmartínM,etal.Primarygraftfailureinhearttransplantation:amultivariateanalysis[J].TransplantProc,1998,30(5):1932.[7]NoonGP,BallJWJr,PapaconstantinouHT.Clinicalex-periencewithBioMedicuscentrifugalventricularsupportin172patients[J].ArtifOrgans,1995,19(7):756-760.[8]NoonGP,BallJWJr,ShortHD.Bio-Medicuscentrifugalventricularsupportforpostcardiotomycardiacfailure:areviewof129cases[J].AnnThoracSurg,1996,61(1):291-295.[9]IbrahimM,HendryP,MastersR,etal.Managementofacutesevereperioperativefailureofcardiacallografts:asingle-centreexperiencewithareviewoftheliterature[J].CanJCardiol,2007,23(5):363-367.[10]KavaranaMN,SinhaP,NakaY,etal.Mechanicalsup-portforthefailingcardiacallograft:asingle-centerexpe-rience[J].JHeartLungTransplant,2003,22(5):542-547.[11]TaghaviS,ZuckermannA,AnkersmitJ,etal.Extracor-porealmembraneoxygenationissuperiortorightventricu-larassistdeviceforacuterightventricularfailureafterhearttransplantation[J].AnnThoracSurg,2004,78(5):1644-1649.[12]ChouNK,ChiNH,KoWJ,etal.Extracorporealmem-braneoxygenationforperioperativecardiacallograftfailure[J].AsaioJ,2006,52(1):100-103.[13]JahaniaMS,MullettTW,SanchezJA,etal.Acuteal-lograftfailureinthoracicorgantransplantation[J].JCardSurg,2000,15(2):122-128.[14]BourgeRC,NaftelDC,Costanzo-NordinMR,etal.Pre-transplantationriskfactorsfordeathafterhearttransplan-tation:amultiinstitutionalstudy.TheTransplantCardiol-ogistsResearchDatabaseGroup[J].JHeartLungTrans-plant,1993,12(4):549-562.[15]DelRizzoDF,MenkisAH,PflugfelderPW,etal.Theroleofdonorageandischemictimeonsurvivalfollowingorthotopichearttransplantation[J].JHeartLungTrans-plant,1999,18(4):310-319.[16]YoungJB,NaftelDC,BourgeRC,etal.Matchingtheheartdonorandhearttransplantrecipient.cluesforsuc-cessfulexpansionofthedonorpool:amultivariable,mul-tiinstitutionalreport.TheCardiacTransplantResearchDatabaseGroup[J].JHeartLungTransplant,1994,13(3):353-364.[17]FernandezJ,ArandaJ,MabbotS,etal.Overseaspro-curementofdonorhearts:ischemictimeeffectonpostop-erativeoutcomes[J].TransplantProc,2001,33(7-8):3803-3804.[18]MinevPA,El-BanayosyA,MinamiK,etal.Differentialindicationformechanicalcirculatorysupportfollowinghearttransplantation[J].IntensiveCareMed,2001,27(8):1321-1327.[19]ChenEP,BittnerHB,DavisRD,etal.Rightventricularadaptationtoincreasedafterloadafterorthotopiccardiactransplantationinthesettingofrecipientchronicpulmona-ryhypertension[J].Circulation,1997,96(9Suppl):Ⅱ-141-147.[20]HsiehCM,MishkelGJ,CardosoPF,etal.Productionandreversibilityofrightventricularhypertrophyandrightheartfailureindogs[J].AnnThoracSurg,1992,54(1):104-110.[21]SalzbergSP,LachatML,vonHarbouK,etal.Normali-zationofhighpulmonaryvascularresistancewithLVADsupportinhearttransplantationcandidates[J].EurJCardiothoracSurg,2005,27(2):222-225.[22]ChaturvediRR,MacraeD,BrownKL,etal.CardiacECMOforbiventricularheartsafterpaediatricopenheartsurgery[J].Heart,2004,90(5):545-551.[23]PizarroC,DavisDA,HealyRM,etal.IstherearoleforextracorporeallifesupportafterstageⅠNorwood?[J]EurJCardiothoracSurg,2001,19(3):294-301.·164·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3体外膜肺氧合在边缘供心移植中的临床应用研究孟旭GURBANOVEmin崔永强韩杰曾文贾一新【摘要】目的探讨体外膜肺氧合(extracorporealmembraneoxygenation,ECMO)用于长时间冷缺血(longcoldischemictime,LCIT)供心心脏移植术的临床疗效。方法2005年2月至2009年4月,11例患者[ECMO环路(intraoperativeECMO,i-ECMO)组]接受LCIT超过7h的供心移植,手术采用i-ECMO进行心肺分流术,术毕直接转为ECMO辅助。同期有11例患者[心肺分流术(stand-ardcardiopulmonarybypass,s-CPB)组,s-CPB组]行冷缺血少于7h的心脏移植手术,术中常规s-CPB,术后接受了ECMO辅助。比较两组的ECMO的总体撤机率、ICU停留时间、浓缩红细胞输注量、左心室射血分数(LVEF)、住院费用、围手术期生存率、术后1年生存率,并了解ECMO相关并发症。结果i-ECMO组和s-CPB组供心缺血时间分别为422~485(平均448)min、110~400(平均218)min,两组间比较差异有统计学意义(P<0.01)。i-ECMO组中10例患者(91%)成功撤离EC-MO并无出院前死亡,1例死于术中大出血(与ECMO无关),s-CPB组中9例(82%)成功撤离EC-MO。心脏移植应用ECMO的总体撤机率为86%。两组术后30d(围手术期)和术后1年的生存率分别为91%和82%、73%和64%,两组比较差异均无统计学意义(P>0.05)。i-ECMO组的ICU停留时间、浓缩红细胞输注量以及住院花费均显著低于对s-CPB组(均为P<0.05)。i-ECMO组的入院和出院LVEF分别为0.23±0.06、0.65±0.12,s-CPB组相应为0.25±0.10、0.66±0.06,两组出院时LVEF均较术前明显升高,但两组比较差异无统计学意义(P>0.05)。ECMO相关并发症及处理:5例患者(23%)因低心排量而应用了主动脉内球囊反搏(IABP),其中3例为成功撤离ECMO的病人,2例为未能撤离ECMO者;6例(27%)患者由于肾功能不全接受了持续肾替代治疗(CRRT),其中2例为成功撤离ECMO,4例为未能撤离ECMO者。结论用边缘供心进行心脏移植术时,术中利用i-ECMO、术毕转为ECMO辅助可以为LCIT的供心提供早期、持续和有效的循环支持,从而在相当程度上改善此类边缘供心的移植成功率。同时,该研究方法还具有ICU停留时间短,浓缩红细胞输注量低和显著节省费用的优点。【关键词】心脏移植;边缘供体;体外膜肺氧合;心肺分流术作者单位:100029首都医科大学附属北京安贞医院心脏外科通讯作者:孟旭,E-mail:mxu@263.net(收稿日期:2010-03-08)(本文编辑:邬加佳朱佩玲)(上接第143页)[5]NickeleitV,ZeilerM,GudatF,etal.DetectionofthecomplementdegradationproductC4dinrenalallografts:diagnosticandtherapeuticimplications[J].JAmSocNephrol,2002,13(1):242-251.[6]RegeleH,ExnerM,WatschingerB,etal.EndothelialC4ddepositionisassociatedwithinferiorkidneyallograftoutcomeindependentlyofcellularrejection[J].NephrolDialTransplant,2001,16(10):2058-2066.[7]CollinsAB,SchneebergerEE,PascualMA,etal.Com-plementactivationinacutehumoralrenalallograftrejec-tion:diagnosticsignificanceofC4ddepositsinperitubularcapillaries[J].JAmSocNephrol,1999,10(10):2208-2214.[8]黄洪锋,陈江华,吴建永,等.双滤过法血浆分离联合达昔单抗预处理肾移植致敏受者的临床效果[J].中华泌尿外科杂志,2005,26(2):97-100.[9]PascualM,SaidmanS,Tolkoff-RubinN,etal.Plasmaexchangeandtacrolimus-mycophenolaterescueforacutehumoralrejectioninkidneytransplantation[J].Trans-plantation,1998,66(11):1460-1464.[10]McDonaldS,RussG,CampbellS,etal.Kidneytrans-plantrejectioninAustraliaandNewZealand:relation-shipsbetweenrejectionandgraftoutcome[J].AmJTransplant,2007,7(5):1201-1208.[11]JosephJT,KingsmoreDB,JunorBJ,etal.Theimpactoflateacuterejectionaftercadaverickidneytransplantation[J].ClinTransplant,2001,15(4):221-227.[12]JianghuaC,WenqingX,HuipingW,etal.C4dasasig-nificantpredictorforhumoralrejectioninrenalallografts[J].ClinTransplant,2005,19(6):785-791.(收稿日期:2010-01-26)(本文编辑:朱佩玲)·165·器官移植2010年5月第1卷第3期OrganTransplant,May2010,Vol.1,No.3
